プラズミノゲン活性化剤阻害剤-1は,動脈血栓溶解抵抗の主要な決定因子です
1Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Circulation
|June 15, 1999
まとめ
プラズミノゲン活性化剤阻害剤-1 (PAI-1) は,組織プラズミノゲン活性化剤 (tPA) が動脈凝固を分解するのを著しく阻害する. PAI-1を阻害すると,凝固溶解戦略が改善される可能性があります.
科学分野:
- バイオケミストリー バイオケミストリー
- 心血管生物学 心血管生物学
- トロンボシス研究研究
背景:
- 血小板に富んだ動脈栓は,組織プラズミノゲン活性化剤 (tPA) による溶解に対する抵抗を示します.
- プラズミノゲン活性化剤阻害剤-1 (PAI-1) は,tPAの既知の阻害剤であり,血栓溶解抵抗に関与しています.
- PAI-1の動脈血栓溶解における役割に関する動物に関するデータは限られている.
研究 の 目的:
- ネズミのモデルで動脈血栓溶解に対するPAI-1の効果を調査する.
- PAI-1が血小板に富んだ動脈血栓のtPA媒介性血栓解体を抑制するという仮説を検証する.
主な方法:
- ネズミの頸動脈損傷モデルを用いて,野生型 (PAI-1 +/+) とPAI-1欠乏型 (PAI-1 -/-) のマウスの血小板豊富な血栓を誘発した.
- 血栓溶解はヘパリン,ヒトプラズミノゲン,およびさまざまな濃度のtPAを用いて誘導された.
- PAI-1の分布と機能を評価するために,組織学的分析と血小板溶解塩酸測定を行った.
主要な成果:
- PAI-1欠乏マウスは,tPAで治療された野生型のマウスと比較して,有意に改善されたリパーフュージョン率と短い溶解時間を示した.
- ヒストロジカル検査により,野生型のマウスのトロンビ内のPAI-1の存在が確認されました.
- 野生型血小板からのリン酸塩はヒトのtPA活性を抑制したが,PAI-1欠乏血小板リン酸塩はそうしなかった.
結論:
- PAI-1は,血小板に富んだ動脈血栓の薬学的なtPA濃度に対する抵抗性を決定する重要な要因です.
- PAI-1を阻害または相殺することを目的とした戦略は,血栓駆除薬療法の有効性を高める可能性があります.
関連する概念動画
01:17Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...